NRx Pharmaceuticals, Inc.
NRXP
$2.34
$0.073.08%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.37% | -6.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.89% | -0.45% | |||
| Operating Income | -10.40% | 0.45% | |||
| Income Before Tax | 66.50% | -218.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 66.50% | -218.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 66.50% | -218.96% | |||
| EBIT | -10.40% | 0.45% | |||
| EBITDA | -10.19% | 0.45% | |||
| EPS Basic | 72.98% | -191.84% | |||
| Normalized Basic EPS | 69.91% | -147.23% | |||
| EPS Diluted | 72.98% | -191.84% | |||
| Normalized Diluted EPS | 69.91% | -147.23% | |||
| Average Basic Shares Outstanding | 23.96% | 9.29% | |||
| Average Diluted Shares Outstanding | 23.96% | 9.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||